AOF
Pfanstiehl, Inc.
Application Filed: 2017-09-23
Trademark Application Details
FIRST EXTENSION - GRANTED
| Research |
OneLook
Acronym Finder
|
| Serial Number | 87619921 |
| Registration Number | 6211471 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Attorney Name | Paul C. Llewellyn |
| Attorney Docket Number | 1041482-0008 |
| Law Office Assigned | L40 |
| Employee Name | BRADLEY, EVELYN W |
Timeline
| 2017-09-23 | Application Filed |
| 2018-02-06 | Published for Opposition |
| 2018-04-03 | Location: INTENT TO USE SECTION |
| 2018-09-10 | Status: Live/Pending |
| 2019-01-02 | Transaction Date |
| 2020-12-01 | Trademark Registered |
Trademark Applicants & Owners
| Owner: |  Pfanstiehl, Inc. |
| Address | 1219 Glen Rock Avenue Waukegan DE 60085 |
| Legal Entity Type | Corporation |
| Legal Entity State | DE |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 1 |
| U.S. Codes: | 001,005,006,010,026,046 |
| International Codes: | 42 |
| U.S. Codes: | 100,101 |
| Type Code | Type |
|---|---|
| GS0421 | Biochemical research and development; Chemical, biochemical, biological and bacteriological research and analysis; Drug discovery services; Pharmaceutical drug development services; Product research and development; Research and development in the pharmaceutical and biotechnology fields; Research and development of vaccines and medicines |
| GS0011 | Chemicals and biochemicals for use in the formulation, development and manufacture of pharmaceuticals, biopharmaceuticals, vaccines, finished drug products, parenteral drugs and therapies; Chemicals and biochemicals for use in biotechnological product development and manufacturing processes; excipients and active ingredients for use in development, formulation and manufacture of pharmaceuticals, biopharmaceuticals, vaccines, injectable formulations, pharmaceutical intermediaries and drug formulations; chemicals, biochemicals, stabilizers, catalysts, enzymes, formulation ingredients, additives, drug delivery molecules and carriers, and buffers, all for use in the pharmaceutical and biopharmaceutical industry; active pharmaceutical ingredients for use in the manufacture of pharmaceuticals, biopharmaceuticals, vaccines, and finished drug products; formulation ingredients, additives, drug delivery molecules, and carriers, and buffers, all for use in the pharmaceutical and biopharmaceutical industry; pharmaceutical intermediates for use in the pharmaceutical and biopharmaceutical industry; biochemical excipients for use in the pharmaceutical and biopharmaceutical industry; biochemical catalysts; biochemical preservers and protectors for use in the pharmaceutical and biopharmaceutical industry |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| NEW APPLICATION ENTERED IN TRAM | 2017-09-27 | 1 NWAP I:Incoming Correspondence |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2017-09-28 | 2 NWOS I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2017-12-29 | 3 DOCK D:Assigned to Examiner |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2017-12-30 | 4 CNSA P: |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2018-01-17 | 5 NONP E:E-Mail |
| PUBLISHED FOR OPPOSITION | 2018-02-06 | 6 PUBO A:Allowance for Publication |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2018-02-06 | 7 NPUB E:E-Mail |
| NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2018-04-03 | 8 NOAM E:E-Mail |
| TEAS EXTENSION RECEIVED | 2018-09-10 | 9 EEXT I:Incoming Correspondence |
| EXTENSION 1 FILED | 2018-09-10 | 10 EXT1 S: |
| EXTENSION 1 GRANTED | 2018-09-10 | 11 EX1G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2018-09-12 | 12 EXRA E:E-Mail |
| TEAS EXTENSION RECEIVED | 2019-03-28 | 13 EEXT I:Incoming Correspondence |
| EXTENSION 2 FILED | 2019-03-28 | 14 EXT2 S: |
| EXTENSION 2 GRANTED | 2019-03-28 | 15 EX2G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2019-03-30 | 16 EXRA E:E-Mail |
| TEAS EXTENSION RECEIVED | 2019-10-02 | 17 EEXT I:Incoming Correspondence |
| EXTENSION 3 FILED | 2019-10-02 | 18 EXT3 S: |
| EXTENSION 3 GRANTED | 2019-10-02 | 19 EX3G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2019-10-04 | 20 EXRA E:E-Mail |
| TEAS EXTENSION RECEIVED | 2020-04-02 | 21 EEXT I:Incoming Correspondence |
| EXTENSION 4 FILED | 2020-04-02 | 22 EXT4 S: |
| EXTENSION 4 GRANTED | 2020-04-02 | 23 EX4G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2020-04-04 | 24 EXRA E:E-Mail |
| TEAS EXTENSION RECEIVED | 2020-09-17 | 25 EEXT I:Incoming Correspondence |
| TEAS STATEMENT OF USE RECEIVED | 2020-09-21 | 26 EISU I:Incoming Correspondence |
| CASE ASSIGNED TO INTENT TO USE PARALEGAL | 2020-10-05 | 27 AITU A:Allowance for Publication |
| USE AMENDMENT FILED | 2020-09-21 | 28 IUAF S: |
| STATEMENT OF USE PROCESSING COMPLETE | 2020-10-05 | 29 SUPC I:Incoming Correspondence |
| ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | 2020-10-24 | 30 CNPR P: |
| NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | 2020-10-27 | 31 SUNA E:E-Mail |
| REGISTERED-PRINCIPAL REGISTER | 2020-12-01 | 32 R.PR A:Allowance for Publication |
Similar Marks
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 